Upregulated Dvl3 was also recently investigated as a biomarker for the recurrence of prostate cancer [54], while its downregulation sensitizes prostate and breast cancer cells to insulin-like growth factor 1 (IGF1) [55]. Here, DVL3 is linked to prostate carcinoma.